Stifel Nicolaus began coverage on shares of Bruker (NASDAQ:BRKR) in a research report sent to investors on Thursday, Briefing.com Automated Import reports. The brokerage issued a hold rating and a $53.00 target price on the medical research company’s stock.
Other analysts also recently issued research reports about the company. Needham & Company LLC set a $58.00 target price on Bruker and gave the company a buy rating in a research note on Friday, September 27th. Bank of America raised Bruker from a neutral rating to a buy rating and set a $52.00 price objective on the stock in a research note on Thursday, September 26th. BidaskClub downgraded Bruker from a buy rating to a hold rating in a research note on Tuesday, August 6th. Zacks Investment Research downgraded Bruker from a hold rating to a sell rating and set a $46.00 price objective on the stock. in a research note on Tuesday, October 15th. Finally, ValuEngine raised Bruker from a sell rating to a hold rating in a research note on Friday, November 1st. One analyst has rated the stock with a sell rating, six have given a hold rating and seven have given a buy rating to the company. The company currently has an average rating of Hold and a consensus price target of $50.91.
Bruker stock traded up $0.82 during mid-day trading on Thursday, hitting $50.30. 630,100 shares of the company’s stock traded hands, compared to its average volume of 745,557. The firm has a 50 day moving average price of $45.23 and a 200 day moving average price of $44.58. The company has a quick ratio of 1.32, a current ratio of 2.23 and a debt-to-equity ratio of 0.67. The company has a market cap of $7.57 billion, a PE ratio of 35.93, a price-to-earnings-growth ratio of 2.42 and a beta of 1.36. Bruker has a one year low of $26.10 and a one year high of $52.23.
Bruker (NASDAQ:BRKR) last announced its earnings results on Thursday, October 31st. The medical research company reported $0.43 earnings per share for the quarter, beating the consensus estimate of $0.38 by $0.05. The firm had revenue of $521.10 million for the quarter, compared to the consensus estimate of $493.52 million. Bruker had a return on equity of 28.02% and a net margin of 10.20%. The firm’s revenue for the quarter was up 11.7% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.37 EPS. On average, analysts expect that Bruker will post 1.62 earnings per share for the current fiscal year.
The company also recently disclosed a quarterly dividend, which will be paid on Friday, December 20th. Stockholders of record on Monday, December 2nd will be paid a $0.04 dividend. This represents a $0.16 dividend on an annualized basis and a dividend yield of 0.32%. The ex-dividend date is Friday, November 29th. Bruker’s dividend payout ratio is presently 11.43%.
In related news, Director Marc A. Kastner sold 3,203 shares of Bruker stock in a transaction on Thursday, November 7th. The stock was sold at an average price of $47.39, for a total value of $151,790.17. Following the transaction, the director now directly owns 7,608 shares in the company, valued at approximately $360,543.12. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, VP Mark Munch sold 47,203 shares of Bruker stock in a transaction on Monday, September 16th. The stock was sold at an average price of $42.87, for a total value of $2,023,592.61. Following the completion of the transaction, the vice president now owns 96,063 shares in the company, valued at $4,118,220.81. The disclosure for this sale can be found here. Insiders sold a total of 66,108 shares of company stock worth $2,849,941 in the last three months. Company insiders own 26.50% of the company’s stock.
Several hedge funds and other institutional investors have recently modified their holdings of the stock. Great Lakes Advisors LLC grew its holdings in shares of Bruker by 2.7% in the 3rd quarter. Great Lakes Advisors LLC now owns 360,009 shares of the medical research company’s stock worth $15,815,000 after acquiring an additional 9,424 shares during the last quarter. Massachusetts Financial Services Co. MA grew its holdings in shares of Bruker by 107.4% in the 3rd quarter. Massachusetts Financial Services Co. MA now owns 46,314 shares of the medical research company’s stock worth $2,034,000 after acquiring an additional 23,986 shares during the last quarter. Tower Research Capital LLC TRC acquired a new position in shares of Bruker in the 3rd quarter worth $179,000. GW&K Investment Management LLC grew its holdings in shares of Bruker by 42.2% in the 3rd quarter. GW&K Investment Management LLC now owns 131,398 shares of the medical research company’s stock worth $5,772,000 after acquiring an additional 38,987 shares during the last quarter. Finally, Sector Gamma AS grew its holdings in shares of Bruker by 38.1% in the 3rd quarter. Sector Gamma AS now owns 308,004 shares of the medical research company’s stock worth $13,531,000 after acquiring an additional 85,000 shares during the last quarter. Institutional investors and hedge funds own 67.79% of the company’s stock.
Bruker Company Profile
Bruker Corporation manufactures and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates in two segments, Bruker Scientific Instruments, and Bruker Energy & Supercon Technologies. It offers life science tools based on magnetic resonance technology; life science mass spectrometry and ion mobility spectrometry solutions; infrared spectroscopy and radiological/nuclear detectors for chemical, biological, radiological, nuclear, and explosive detection in emergency response, homeland security, and defense applications; and research, analytical, and process analysis instruments and solutions based on infrared and Raman molecular spectroscopy technologies.
Further Reading: Profit margin is different from the revenue
Receive News & Ratings for Bruker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bruker and related companies with MarketBeat.com's FREE daily email newsletter.